Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
BELTRAMI, GERMANA
PhALLCON, NCT03589326 / 2018-000397-30: A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020 Sep 2019 - Sep 2019: Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020 Initiation of new trial in Ph+ ALL Jul 2018 - Jul 2018: Initiation of new trial in Ph+ ALL	Active, not recruiting	3	245	Europe, Canada, Japan, US, RoW	Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone	Takeda	Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)	08/22	07/27
NCT04168502 / 2019-003871-20: Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML	Recruiting	3	414	Europe	Gemtuzumab Ozogamicin	Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus, Pfizer S.R.L.	Acute Myeloid Leukemia	04/25	04/27
DEC GITMO, NCT04476199 / 2020-002297-26: Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCT	Active, not recruiting	2	100	Europe	Venetoclax and Decitabine	Gruppo Italiano Trapianto di Midollo Osseo, Abbvie, Janssen	Acute Myeloid Leukemia	02/23	06/25
IDIOME-STUDY, NCT03503409: IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome	Active, not recruiting	2	68	Europe	AG-120	Groupe Francophone des Myelodysplasies	Myelodysplastic Syndromes, Acute Myeloid Leukemia	04/25	04/25
NCT03751917: Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic Leukemia	Recruiting	N/A	100	Europe	Arsenic Trioxide, ATRA+ATO	Gruppo Italiano Malattie EMatologiche dell'Adulto	Acute Promyelocytic Leukemia	12/24	12/24

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
BELTRAMI, GERMANA
PhALLCON, NCT03589326 / 2018-000397-30: A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020 Sep 2019 - Sep 2019: Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020 Initiation of new trial in Ph+ ALL Jul 2018 - Jul 2018: Initiation of new trial in Ph+ ALL	Active, not recruiting	3	245	Europe, Canada, Japan, US, RoW	Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone	Takeda	Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)	08/22	07/27
NCT04168502 / 2019-003871-20: Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML	Recruiting	3	414	Europe	Gemtuzumab Ozogamicin	Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus, Pfizer S.R.L.	Acute Myeloid Leukemia	04/25	04/27
DEC GITMO, NCT04476199 / 2020-002297-26: Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCT	Active, not recruiting	2	100	Europe	Venetoclax and Decitabine	Gruppo Italiano Trapianto di Midollo Osseo, Abbvie, Janssen	Acute Myeloid Leukemia	02/23	06/25
IDIOME-STUDY, NCT03503409: IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome	Active, not recruiting	2	68	Europe	AG-120	Groupe Francophone des Myelodysplasies	Myelodysplastic Syndromes, Acute Myeloid Leukemia	04/25	04/25
NCT03751917: Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic Leukemia	Recruiting	N/A	100	Europe	Arsenic Trioxide, ATRA+ATO	Gruppo Italiano Malattie EMatologiche dell'Adulto	Acute Promyelocytic Leukemia	12/24	12/24